$IOVA (Iovance Biotherapeutics, Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 77.5%)

Graded daily on value D-, growth A-, profitability D, momentum A+, revisions D-. Sector-relative, identical for every user.

Most active credible voices on $IOVA

@pharmdca (Pharmdca) — 30 mentions · 105.3K followers
@zohmbastic (zohm) — 22 mentions · 11.4K followers
@stevedjacobs (Steve Jacobs) — 16 mentions · 17.0K followers

Recent headlines featuring $IOVA

2026-10-29: IOVA discussed in daily headlines

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $IOVA are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

For richer charts and full features, open SpikePanel on desktop.

$IOVA — what investors on X are saying · SpikePanel

$IOVAIovance Biotherapeutics, Inc. · Biotechnology · $4.0B

$8.79

-0.4%

Event thread

Key events, in time order

10 items

2026-10-308-K filing
8-K: Item 8.01, Item 9.01
D1 -11.3% · since +4.1%
2026-10-068-K filing
8-K: Item 8.01, Item 9.01
D1 -8.4% · +5d +11.9%

8 earlier events

2026-09-30EarningsBull
Iovance Raises 2026 Revenue Guidance to $410-$420M; Stock Hits 52-Week High
Strong demand for Amtagvi and Proleukin drives guidance raise; shares surge 31.5% to $14.45
D1 +2.6% · +5d -12.8%
2 waves of this story
- 2026-09-30 Strong US demand for Amtagvi and Proleukin drives higher outlook
- 2026-09-30 Strong demand for Amtagvi and Proleukin drives guidance raise; shares surge 31.5% to $14.45
2026-09-298-K filing
8-K: Item 8.01, Item 9.01
D1 +31.5% · +5d -10.3%
2026-09-24AnalystBull
Goldman Initiates IOVNA Buy with ~40% Upside
Goldman resumes coverage with Buy rating, citing nearly 40% upside
D1 +6.0% · +5d +31.8%
2 waves of this story
- 2026-09-24 GS sees inflection in Amtagvi launch; logistical/operational challenges easing
- 2026-09-24 Goldman resumes coverage with Buy rating, citing nearly 40% upside
2026-08-21Other
IOVA Hits 52-Week High, Up Over 200% YTD
Multiple sources confirm new high without company news, sentiment-driven
D1 -7.8% · +5d -3.4%
2026-08-06 → 08-20Earnings
IOVA Record Q2 Revenue, Analyst Raises PT
UBS raises PT to $7 from $4, keeps Neutral, Amtagvi revenue $91M
D1 +43.1% · +5d +5.0%
4 waves of this story
- 2026-08-06 Revenue up 66% YoY, gross margin 56%, US Amtagvi ~$91M
- 2026-08-06 Q2 revenue up 66% YoY; US Amtagvi ~$91M; loss beats consensus
- 2026-08-08 Q2 results continue to resonate, stock hits 52-week high; market eyes upcoming lung cancer data catalyst
- 2026-08-20 UBS raises PT to $7 from $4, keeps Neutral, Amtagvi revenue $91M
2026-08-068-K filing
8-K: Item 8.01, Item 9.01
D1 +43.1% · +5d +5.0%
2026-08-06Earnings
Earnings report
第二季度总收入超过99百万美元，同比增长66%，环比增长39%，创历史新高。
D1 +43.1% · +5d +5.0%
2026-08-06RegulationBull
FDA Grants FTD for Lifileucel in Soft Tissue Sarcoma
Regulatory milestone; NSCLC update expected 4Q26
D1 +43.1% · +5d +5.0%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

10 items

2026-10-308-K filing
8-K: Item 8.01, Item 9.01
D1 -11.3% · since +4.1%
2026-10-068-K filing
8-K: Item 8.01, Item 9.01
D1 -8.4% · +5d +11.9%
2026-09-30EarningsBull
Iovance Raises 2026 Revenue Guidance to $410-$420M; Stock Hits 52-Week High
Strong demand for Amtagvi and Proleukin drives guidance raise; shares surge 31.5% to $14.45
D1 +2.6% · +5d -12.8%
2 waves of this story
- 2026-09-30 Strong US demand for Amtagvi and Proleukin drives higher outlook
- 2026-09-30 Strong demand for Amtagvi and Proleukin drives guidance raise; shares surge 31.5% to $14.45
2026-09-298-K filing
8-K: Item 8.01, Item 9.01
D1 +31.5% · +5d -10.3%
2026-09-24AnalystBull
Goldman Initiates IOVNA Buy with ~40% Upside
Goldman resumes coverage with Buy rating, citing nearly 40% upside
D1 +6.0% · +5d +31.8%
2 waves of this story
- 2026-09-24 GS sees inflection in Amtagvi launch; logistical/operational challenges easing
- 2026-09-24 Goldman resumes coverage with Buy rating, citing nearly 40% upside

5 earlier events

2026-08-21Other
IOVA Hits 52-Week High, Up Over 200% YTD
Multiple sources confirm new high without company news, sentiment-driven
D1 -7.8% · +5d -3.4%
2026-08-06 → 08-20Earnings
IOVA Record Q2 Revenue, Analyst Raises PT
UBS raises PT to $7 from $4, keeps Neutral, Amtagvi revenue $91M
D1 +43.1% · +5d +5.0%
4 waves of this story
- 2026-08-06 Revenue up 66% YoY, gross margin 56%, US Amtagvi ~$91M
- 2026-08-06 Q2 revenue up 66% YoY; US Amtagvi ~$91M; loss beats consensus
- 2026-08-08 Q2 results continue to resonate, stock hits 52-week high; market eyes upcoming lung cancer data catalyst
- 2026-08-20 UBS raises PT to $7 from $4, keeps Neutral, Amtagvi revenue $91M
2026-08-068-K filing
8-K: Item 8.01, Item 9.01
D1 +43.1% · +5d +5.0%
2026-08-06Earnings
Earnings report
第二季度总收入超过99百万美元，同比增长66%，环比增长39%，创历史新高。
D1 +43.1% · +5d +5.0%
2026-08-06RegulationBull
FDA Grants FTD for Lifileucel in Soft Tissue Sarcoma
Regulatory milestone; NSCLC update expected 4Q26
D1 +43.1% · +5d +5.0%

$IOVA (Iovance Biotherapeutics, Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 77.5%)

Most active credible voices on $IOVA

Recent headlines featuring $IOVA

$IOVA (Iovance Biotherapeutics, Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 77.5%)

Most active credible voices on $IOVA

Recent headlines featuring $IOVA

8-K: Item 8.01, Item 9.01

8-K: Item 8.01, Item 9.01

Iovance Raises 2026 Revenue Guidance to $410-$420M; Stock Hits 52-Week High

8-K: Item 8.01, Item 9.01

Goldman Initiates IOVNA Buy with ~40% Upside

IOVA Hits 52-Week High, Up Over 200% YTD

IOVA Record Q2 Revenue, Analyst Raises PT

8-K: Item 8.01, Item 9.01

Earnings report

FDA Grants FTD for Lifileucel in Soft Tissue Sarcoma

Bull vs bear

Discussion

8-K: Item 8.01, Item 9.01

8-K: Item 8.01, Item 9.01

Iovance Raises 2026 Revenue Guidance to $410-$420M; Stock Hits 52-Week High

8-K: Item 8.01, Item 9.01

Goldman Initiates IOVNA Buy with ~40% Upside

IOVA Hits 52-Week High, Up Over 200% YTD

IOVA Record Q2 Revenue, Analyst Raises PT

8-K: Item 8.01, Item 9.01

Earnings report

FDA Grants FTD for Lifileucel in Soft Tissue Sarcoma